Allosteric inhibition of the PCSK9–LDLR interaction: structural insights for small molecule design
Physical Chemistry Chemical Physics · 2025 · 27 (45) · 24534-24544
DOI: 10.1039/d5cp03269e ↗Kurz gefasst
Fachartikel in der Zeitschrift Physical Chemistry Chemical Physics, 2025. Verfasst von Yong Su Baek und 3 weiteren Autor:innen. Beteiligte Einrichtung: Atomatrix, 851, Daewangpangyo-ro 815, Sujeong-gu, Seongnam-si, Gyeonggi-do, Korea. sblee@atomatrix.co.kr. Hauptthemen laut MEDLINE: Receptors, LDL, Proprotein Convertase 9, Small Molecule Libraries, PCSK9 Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates plasma LDL cholesterol levels through direct interaction with the LDL receptor (LDLR), making it a clinically validated target for lipid-lowering therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Atomatrix, 851, Daewangpangyo-ro 815, Sujeong-gu, Seongnam-si, Gyeonggi-do, Korea. sblee@atomatrix.co.kr.
Zitieren
APA
Baek, Y. S., Kim, S., Lee, E., & Lee, S. (2025). Allosteric inhibition of the PCSK9–LDLR interaction: structural insights for small molecule design. Physical Chemistry Chemical Physics, 27(45), 24534-24544. https://doi.org/10.1039/d5cp03269e
Vancouver
Baek YS, Kim S, Lee E, Lee S. Allosteric inhibition of the PCSK9–LDLR interaction: structural insights for small molecule design. Physical Chemistry Chemical Physics. 2025;27(45):24534-24544. doi:10.1039/d5cp03269e
BibTeX
@article{Baek2025,
author = {Baek, Yong Su and Kim, Siwoo and Lee, Eunho and Lee, Sangbae},
title = {Allosteric inhibition of the PCSK9–LDLR interaction: structural insights for small molecule design},
journal = {Physical Chemistry Chemical Physics},
year = {2025},
volume = {27},
number = {45},
pages = {24534--24544},
doi = {10.1039/d5cp03269e}
}
EUVIMED